

Could Metabolic Therapy Become a Viable Alternative to the Standard of Care for Managing Glioblastoma?

Thomas N Seyfried, PhD,¹ Jeremy Marsh, MSV,² Purna Mukherjee, PhD,³ Giulio Zuccoli, MD⁴ and Dominic P D'Agostino, PhD⁵

1. Professor of Biology; 2 Bachelor of Science; 3. Research Assistant Professor, Biology Department, Boston College, Chestnut Hill, Massachusetts, US; 4. Section Chief, Section of Neuroradiology, Children's Hospital of Pittsburgh, and Associate Professor of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, US; 5. Assistant Professor, Department of Molecular Pharmacology and Physiology, University of South Florida, Tampa, Florida, US

Citation: *US Neurology*, 2014;10(2):v[online only]

Erratum to: *US Neurology*, 2014;10(1):48–55

In order to comply with the latest recommendations outlined by ICMJE the publisher would like to make the following amendments to the Disclosure section of the above-mentioned paper: Thomas N Seyfried, Jeremy Marsh, Purna Mukherjee, Giulio Zuccoli and Dominic P D'Agostino declare no conflict of interest. No funding was received for the publication of this article.